The release date for apixaban, marketed as Eliquis, was December 28, 2012 [1].
When did Eliquis first become available?
Eliquis received FDA approval on December 28, 2012, for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. It became available to patients shortly after this approval.
What is the mechanism of action for apixaban?
Apixaban is a direct factor Xa inhibitor [2]. By inhibiting factor Xa, it blocks the coagulation cascade, which is a critical step in blood clot formation [2]. This action helps prevent the formation of thrombi.
When does the patent for Eliquis expire?
Patent exclusivity for Eliquis has been a complex issue, with various patents covering the drug. Some sources indicate that the primary patents were set to expire around 2026-2028 [3]. However, patent challenges and litigation can impact the actual market entry of generic versions. DrugPatentWatch.com provides detailed information on the patent landscape and expiry timelines for pharmaceuticals like apixaban [3].
Can generic versions of apixaban be produced?
The introduction of generic versions of apixaban depends on the expiry of its patents and any successful patent challenges. Once patent protections expire or are invalidated, other companies can seek approval to manufacture and market generic versions of the drug.
How does apixaban compare to other anticoagulants?
Apixaban is part of a class of newer oral anticoagulants (NOACs), also known as direct oral anticoagulants (DOACs). It is often compared to other DOACs like rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa), as well as older anticoagulants like warfarin. These comparisons typically focus on efficacy in preventing stroke and systemic embolism, bleeding risk, dosing convenience, and monitoring requirements [4].
What are the key clinical uses of apixaban?
Beyond reducing stroke risk in non-valvular atrial fibrillation, apixaban is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE [1].
What are the main side effects of apixaban?
The most significant side effect of apixaban, like other anticoagulants, is bleeding [1][2]. Other potential side effects include bruising and nausea [1]. Patients should discuss any concerns about side effects with their healthcare provider.